Search

Your search keyword '"Ponferrada-Díaz Á"' showing total 30 results
Start Over Author "Ponferrada-Díaz Á"
30 results on '"Ponferrada-Díaz Á"'

1. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

Author

Casanova, María José, Caballol, Berta, García, María José, Mesonero, Francisco, Rubín de Célix, Cristina, Suárez-Álvarez, Patricia, Ferreiro-Iglesias, Rocío, Martín-Rodríguez, María del Mar, de Francisco, Ruth, Varela-Trastoy, Pilar, Bastida, Guillermo, Carrillo-Palau, Marta, Núñez-Ortiz, Andrea, Ramírez-de la Piscina, Patricia, Ceballos, Daniel, Hervías-Cruz, Daniel, Muñoz-Pérez, Roser, Velayos, Benito, Bermejo, Fernando, Busquets, David, Cabacino, Manuel, Camo-Monterde, Patricia, Marín-Jiménez, Ignacio, Muñoz, Carmen, de la Peña-Negro, Luisa Carmen, Sierra-Moros, Eva, Barrio, Jesús, Brunet-Mas, Eduard, Bujanda, Luis, Cañete, Fiorella, Gomollón, Fernando, Manceñido-Marcos, Noemí, Rodríguez-Lago, Iago, Rodríguez-Grau, María Carmen, Sicilia, Beatriz, Torra-Alsina, Sandra, Arranz-Hernández, Laura, Carpio, Daniel, García-Sepulcre, Mariana Fe, González-Muñoza, Carlos, Huguet, José María, Márquez-Mosquera, Lucía, López-Serrano, María Pilar, Ponferrada-Díaz, Ángel, Chaparro, María, and Gisbert, Javier P.

Published
2024
Full Text
View/download PDF

2. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

Author

Márquez-Mosquera, Lucía, Madero, Lucia, Esteve, María, Monfort, David, Varela, Pilare, Vega, Pablo, Martínez, Guillermo Alcaín, Rodriguez-Lago, Iago, García-Bosh, Orlando, Pérez Calle, Jose Lázaro, Merino, Olga, Sierra Ausin, Mónica, Tardillo, Carlos, Lorente Poyatos, Rufo, Fernandez-Salazar, Luis Ignacio, García Sepulcre, Mariana Fe, Bermejo, Fernando, Arce, Nuria Maroto, Bujanda, Luis, Riera, Joan, Ber, Yolanda, Ponferrada Díaz, Ángel, BasCutrina, Francesc, Martinez Montiel, Pilar, Ramos, Laura, Llaó, Jordina, Barreiro- de Acosta, Manuel, Rodriguez Gutierrez, Cristina, Muñoz, Fernando, Sese, Eva, Blat, Rosa, Huguet, Jose M., Marín-Jiménez, Ignacio, Martínez-Flores, Carlos, Van Domselaar, Manuel, Lucendo, Alfredo J., Ginard, Daniel, Menacho, Margarita, Marcos, Noemí Manceñido, Almela, Pedro, de la Piscina, Patricia Ramirez, Argüelles-Arias, Federico, Vilafranca, Carmen Muñoz, Peña, Elena, Alvarez, Pau Gilabert, Santos Fernández, Javier, Coronel, Ana Fuentes, Hernández Villalba, Luis, Andres, Pilar Robledo, Martínez Perez, Teresa, Legido Gil, Jesús, Fernandez, Hipólito, Castillo Regalado, Edgar, Buendía, Lidia, Trapero Martinez, Ana María, Leal, Carles, Miyashiro, Eduardo Iyo, García Herola, Antonio, Frago, Santiago, Novella Duran, María Teresa, Navas López, Victor Manuel, de Prado, Isabel Nicolás, Bebia, Paloma, Botella, Belén, Muñoz, Rosa Ana, Gargallo-Puyuelo, Carla J., Ricart, Elena, Iglesias, Eva, de Francisco, Ruth, Gisbert, Javier P., Taxonera, Carlos, Mañosa, Miriam, Aguas Peris, Mariam, Navarrete-Muñoz, Eva María, Sanahuja, Ana, Guardiola, Jordi, Mesonero, Francisco, Rivero Tirado, Montserrat, Barrio, Jesús, Vera Mendoza, Isabel, de Castro Parga, Luisa, García-Planella, Esther, Calvet, Xavier, Martín Arranz, María Dolores, García, Santiago, Sicilia, Beatriz, Carpio, Daniel, Domenech, Eugeni, and Gomollón, Fernando

Published
2024
Full Text
View/download PDF

3. P1170 Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU

Author

Chaparro, M, primary, Garre, A, additional, Núñez Ortiz, A, additional, Rubio, S, additional, Diz-Lois Palomares, M T, additional, Riestra, S, additional, Alonso-Galán, H, additional, Fernández-Salgado, E, additional, Ferreiro-Iglesias, R, additional, Vela, M, additional, Ponferrada Díaz, Á, additional, Sánchez Rodríguez, E, additional, Hernández, V, additional, Arias García, L, additional, Barrio, J, additional, Huguet, J M, additional, Ginard, D, additional, Rivero, M, additional, Vera, I, additional, Alonso-Abreu, I, additional, Benítez, J M, additional, Aguas, M, additional, Rodríguez-Lago, I, additional, Calvet, X, additional, Fernández-Salazar, L, additional, Echarri, A, additional, Arroyo, M T, additional, Navarro-Llavat, M, additional, Vega, P, additional, Sierra, M, additional, Guerra del Río, E, additional, Vicente, R, additional, Casanova, M J, additional, Navarro, P, additional, Ortiz de Zarate, J, additional, Varela Trastoy, P, additional, Spicakova, K, additional, Gutiérrez, A, additional, Martín-Arranz, M D, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

4. P1115 Characteristics and management of pyoderma gangrenosum and erythema nodosum in patients with inflammatory bowel disease: PIONOSO multicenter study

Author

Rodríguez-Lago, I, primary, Vela, M, additional, Ordás, I, additional, de Francisco, R, additional, Martín-Arranz, M D, additional, Calafat, M, additional, Taxonera, C, additional, Mesonero, F, additional, Fuentes-Valenzuela, E, additional, Granja, A, additional, Ponferrada-Díaz, Á, additional, Varela, P, additional, Zabana, Y, additional, Madero, L, additional, López-Cauce, B, additional, Carrillo, M, additional, Laredo, V, additional, Brunet, E, additional, Rivero, M, additional, Polo, C, additional, Gisbert, J P, additional, Rodríguez, C, additional, Suria, C, additional, Lorente, R, additional, Elorza, A, additional, Sicilia, B, additional, Muñoz-Villafranca, M D C, additional, Mínguez, A, additional, Ferreiro-Iglesias, R, additional, Pajares, R, additional, Castro-Poceiro, J, additional, Surís, G, additional, Roig, C, additional, Mena, R, additional, Lucendo, A J, additional, de la Peña, L, additional, Iyo, E, additional, Ber, Y, additional, Domènech, E, additional, and Barreiro-de Acosta, M, additional

Published
2024
Full Text
View/download PDF

5. P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study)

Author

Giordano, A, primary, Pérez Martínez, I, additional, Gisbert, J P, additional, Ricart, E, additional, M Dolores, M A, additional, Mesonero, F, additional, M Luisa, D C P, additional, Rivero, M, additional, Iglesias Flores, E, additional, Fernández-Prada, S, additional, Calafat, M, additional, Arroyo Villarino, M, additional, de Jorge Turrión, M Á, additional, Rodríguez-González, E, additional, Corsino Roche, P, additional, Carpio, D, additional, Brunet, E, additional, Rodriguez Moranta, F, additional, Arias García, L, additional, Pascual, I, additional, Bermejo, F, additional, Madero, L, additional, Esteve, M, additional, González Muñoza, C, additional, Martínez-Montiel, P, additional, Huguet, J M, additional, Pérez Calle, J L, additional, Rodríguez-Lago, I, additional, Sierra Ausín, M, additional, Lorente Poyatos, R H, additional, García-Bosch, O, additional, Surís Marín, G, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Barreiro-de Acosta, M, additional, Bujanda, L, additional, Blat Serra, R, additional, Ramos, L, additional, Domènech, E, additional, and Garcia Planella, E, additional

Published
2024
Full Text
View/download PDF

7. P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry

Author

Iborra Colomino, M I, primary, Garrido Marín, A, additional, Caballol Oliva, B, additional, Huguet Malavés, J M, additional, Arias García, L, additional, Mesonero Gismero, F, additional, Fernández Prada, S J, additional, Boscá Watts, M M, additional, Ponferrada Díaz, Á, additional, Calvet Calvo, X, additional, Gutiérrez Casbas, A, additional, Ordás Jiménez, I, additional, Ruiz Sanchez, L, additional, Sicilia Aladren, B, additional, Garcia de la Filia, I, additional, Domènech Morral, E, additional, and Nos Mateu, P, additional

Published
2023
Full Text
View/download PDF

13. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina

Subjects
index, Pronòstic mèdic, Risk factors in diseases, COVID-19 (Malaltia), Article, Inflammatory bowel disease, Comorbiditat, inflammatory bowel disease, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH], Factors de risc en les malalties, SARS-CoV-2, COVID-19, determinants, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Prognosis, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], infection, epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA], Medicine, Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació
Abstract

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.

Published
2022

15. OP20 Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study

Author

Chaparro, M, primary, Garre, A, additional, Núñez Ortiz, A, additional, Diz-Lois Palomares, M T, additional, Rodríguez, C, additional, Riestra, S, additional, Vela, M, additional, Benítez, J M, additional, Fernández Salgado, E, additional, Sánchez Rodríguez, E, additional, Hernández, V, additional, Ferreiro-Iglesias, R, additional, Ponferrada Díaz, Á, additional, Barrio, J, additional, Huguet, J M, additional, Arias, L, additional, Martín-Arranz, M D, additional, Calvet, X, additional, Ginard, D, additional, Alonso-Abreu, I, additional, Fernández-Salazar, L, additional, Varela Trastoy, P, additional, Rivero, M, additional, Vera-Mendoza, I, additional, Vega, P, additional, Navarro, P, additional, Sierra, M, additional, Cabriada, J L, additional, Aguas, M, additional, Vicente, R, additional, Navarro-Llavat, M, additional, Echarri, A, additional, Gomollón, F, additional, Guerra del Río, E, additional, Casanova, M J, additional, Spicakova, K, additional, Ortiz de Zarate, J, additional, Alonso-Galán, H, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

16. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

Author

Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Vera, I, additional, Martín, M D, additional, Guerra, I, additional, Gisbert, J P, additional, Mesonero, F, additional, Benítez, O, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Piqueras, M, additional, Lucendo, A, additional, Caballol, B, additional, Mañosa, M, additional, Martínez-Montiel, P, additional, Bosca-Watts, M, additional, Gordillo, J, additional, Bujanda, L, additional, Manceñido, N, additional, Martínez-Pérez, T, additional, López, A, additional, Rodríguez, C, additional, García-López, S, additional, Vega, P, additional, Rivero, M, additional, Melcarne, L, additional, Calvo, M, additional, Iborra, M, additional, Barreiro-de Acosta, M, additional, Arias, L, additional, Barrio, J, additional, Pérez, J L, additional, Busquets, D, additional, Pérez-Martínez, I, additional, Navarro-Llavat, M, additional, Hernández, V, additional, Argüelles-Arias, F, additional, Domènech, E, additional, and Esteve, M, additional

Published
2021
Full Text
View/download PDF

17. 36 - EFECTIVIDAD Y SEGURIDAD DE LA TERAPIA CON USTEKINUMAB Y VEDOLIZUMAB EN PACIENTES CON FÍSTULA PERIANAL COMPLEJA: ESTUDIO HEAL

Author

Casanova, María José, Chaparro, María, Caballol, Berta, García, María José, Mesonero, Francisco, de Célix, Cristina Rubín, Suárez-álvarez, Patricia, Ferreiro-Iglesias, Rocío, del Mar Martín-Rodríguez, María, de Francisco, Ruth, Varela-Trastoy, Pilar, Bastida, Guillermo, Carrillo-Palau, Marta, Núñez-Ortiz, Andrea, Piscina, Patricia Ramírez-de la, Ceballos, Daniel, Hervías-Cruz, Daniel, Muñoz-Pérez, Roser, Velayos, Benito, Bermejo, Fernando, Busquets, David, Cabacino, Manuel, Camo-Monteverde, Patricia, Marín-Jiménez, Ignacio, Muñoz, Carmen, de la Peña-Negro, Luisa Carmen, Sierra-Moros, Eva, Barrio, Jesús, Brunet-Mas, Eduard, Bujanda, Luis, Cañete, Fiorella, Gomollón, Fernando, Manceñido-Marcos, Noemí, Rodríguez-Lago, Iago, Rodríguez-Grau, María Carmen, Sicilia, Beatriz, Torra-Alsina, Sandra, Arranz-Hernández, Laura, Carpio, Daniel, García-Sepulcre, Mariana Fe, González-Muñoza, Carlos, Huguet, José María, Márquez-Mosquera, Lucía, López-Serrano, María Pilar, Ponferrada-Díaz, Ángel, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

18. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Author

Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional

Published
2019
Full Text
View/download PDF

19. Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease

Author

Chaparro, Maria, Burgueno, Paula, Vera, Isabel, Bermejo, Fernando, Marin-Jimenez, Ignacio, Yela, C., Martín Arranz, Maria Dolores, Lopez-Serrano, Pilar, Taxonera, Carlos, Botella, Belén, Pajares, R., Ponferrada Díaz, Angel, Calvo, Marta, Algaba, Alicia, Pérez-Carazo, Leticia, Casis, Begoña, Mate, J., and Gisbert, Javier P.

Published
2011
Full Text
View/download PDF

20. Phenotypic Concordance in Familial Inflammatory Bowel Disease (IBD)

Author

Cabré, Eduard, Mañosa, Míriam, García-Sánchez, Valle, Gutiérrez, Ana, Panes, Julian, Esteve, Maria, Peñalva, Mireia, Nos, Pilar, Merino, Olga, Ponferrada Díaz, Angel, Gisbert, Javier P., Garcia-Planella, Esther, Ceña, Gloria, Cabriada, Jose Luis, Montoro, Miguel A., and Domènech, Eugeni

Published
2011
Full Text
View/download PDF

24. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Author

Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, and Gisbert JP

Subjects
Humans, Male, Female, Retrospective Studies, Adult, Middle Aged, Treatment Outcome, Remission Induction, Severity of Illness Index, Ustekinumab therapeutic use, Colitis, Ulcerative drug therapy
Abstract

Background: Ustekinumab is approved for ulcerative colitis (UC)., Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice., Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission., Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow-up (median 12 months). Rate of discontinuation was 20% per patient-year of follow-up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1-2.1), steroids at baseline (HR 1.5; 95% CI 1.06-2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09-2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid-free clinical remission. Moderate-severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2-0.5), male sex (OR 0.5; 95% CI 0.4-0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6-0.8) were associated with lower likelihood of steroid-free clinical remission at week 16. One hundred and seventy-six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune-mediated diseases., Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies., (© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

25. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.

Author

Ferreiro-Iglesias R, Porto Silva S, Marín S, Casanova MJ, Mañosa M, González-Muñoza C, de Francisco R, Caballol B, Arias L, Piqueras M, Zabana Y, Rivero M, Calvet X, Mesonero F, Varela Trastoy P, Busta Nistal R, Gómez Perosanz R, Vega P, Gonzalez-Vivo M, Iborra M, Bermejo F, Madero L, Rodríguez-Lago I, Rodríguez Gonzalez M, Vera I, Ponferrada Díaz Á, Vela M, Torrealba Medina L, Van Domselaar M, Gomollón F, Iglesias E, Gisbert JP, Calafat M, Giordano A, Pérez-Martínez I, Ricart E, Sicilia B, Mena R, Esteve M, Rivas C, Brunet-Mas E, Fernández C, de Jorge Turrión MÁ, Velayos Jiménez B, Quiñones Calvo M, Regueiro Expósito C, Márquez-Mosquera L, Nos P, Granja A, Gutiérrez A, Cabriada JL, Hervías Cruz D, Calvo M, Pérez Pérez J, Rodríguez Díaz Y, Busquets Casal D, Menacho M, Leal C, Lucendo AJ, Royo V, Olivares S, Álvarez Herrero B, Carrillo-Palau M, Gilabert Álvarez P, Manceñido Marcos N, Martínez-Pérez TJ, Muñoz Villafranca MC, Almela P, Argüelles-Arias F, Legido J, Fuentes Coronel AM, Nieto L, Domènech E, and Barreiro-de Acosta M

Subjects
Humans, Male, Female, Middle Aged, Adult, Aged, Prospective Studies, Registries, Proctitis drug therapy, Colitis, Ulcerative drug therapy, Immunosuppressive Agents therapeutic use
Abstract

Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials. Our aim was to describe the characteristics of patients with refractory UP and their disease-related complications, and to identify the need for immunosuppressive therapies., Methods: We identified patients with UP from the prospective ENEIDA registry sponsored by the GETECCU. We evaluated socio-demographic data and complications associated with immunosuppression. We defined immunosuppression as the use of immunomodulators, biologics and/or small molecules. We used logistic regression to identify factors associated with immunosuppressive therapy., Results: From a total of 34,716 patients with ulcerative colitis, we identified 6281 (18.1%) with UP; mean ± SD age 53 ± 15 years, average disease duration of 12 ± 9 years. Immunosuppression was prescribed in 11% of patients, 4.2% needed one biologic agent and 1% needed two; 2% of patients required hospitalisation, and 0.5% underwent panproctocolectomy or subtotal colectomy. We identified 0.2% colorectal tumours and 5% extracolonic tumours. Patients with polyarthritis (OR 3.56, 95% CI 1.86-6.69; p < 0.001) required immunosuppressants., Conclusions: Among patients with refractory UP, 11% required immunosuppressant therapy, and 4.2% required at least one biologic agent., (© 2024 John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

26. Falciform ligament thrombosis after umbilical vein recanalization in the setting of acute pancreatitis, a rare entity.

Author

Escobar Ortiz J, Pérez Pérez J, Adán Merino L, Muñoz Roldán C, Barcina García E, and Ponferrada Díaz Á

Subjects
Humans, Male, Aged, Ligaments surgery, Thrombosis etiology, Thrombosis diagnostic imaging, Acute Disease, Tomography, X-Ray Computed, Venous Thrombosis etiology, Venous Thrombosis diagnostic imaging, Umbilical Veins diagnostic imaging, Pancreatitis etiology, Pancreatitis diagnostic imaging
Abstract

We present the case of a 79-year-old man who presents falciform ligament thrombosis after umbilical vein recanalization as an uncommon complication of acute pancreatitis. The performance of abdomino-pelvic CT with contrast, allowed its diagnosis, as well as the establishment of an adequate treatment with favorable evolution.

Published
2024
Full Text
View/download PDF

27. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Author

Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, De Francisco R, García-Alonso FJ, Sanahuja A, Gargallo-Puyuelo CJ, Mesonero F, Casanova MJ, Mañosa M, Rivero M, Calvo M, Sierra-Ausin M, González-Muñoza C, Calvet X, García-López S, Guardiola J, Arias García L, Márquez-Mosquera L, Gutiérrez A, Zabana Y, Navarro-Llavat M, Lorente Poyatos R, Piqueras M, Torrealba L, Bermejo F, Ponferrada-Díaz Á, Pérez-Calle JL, Barreiro-de Acosta M, Tejido C, Cabriada JL, Marín-Jiménez I, Roncero Ó, Ber Y, Fernández-Salazar L, Camps Aler B, Lucendo AJ, Llaó J, Bujanda L, Muñoz Villafranca C, Domènech E, Chaparro M, and Gisbert JP

Abstract

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.

Published
2024
Full Text
View/download PDF

28. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, P Gisbert J, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, J Lucendo A, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Pérez Calle JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, Ortiz de Zarate J, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, and On Behalf Of The Eneida Registry Of Geteccu

Abstract

(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3−5.9), occupational risk (OR: 2.9; 95%CI: 1.8−4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2−2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09−0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

Published
2022
Full Text
View/download PDF

29. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10 , 2885.

Author

Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, and On Behalf Of The EpidemIBD Study Group Of Geteccu

Abstract

The authors wish to make the following corrections to this paper [...].

Published
2022
Full Text
View/download PDF

30. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Author

Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, and Gisbert JP

Abstract

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results